Forward P/S Multiple: cbdMD, Inc. (YCBD)

Graphic logo of cbdMD Inc. (YCBD)

The growth dynamics of cbdMD, Inc. (YCBD) are based on the creation of a closed subscription ecosystem for wellness products, as confirmed by the forward P/S history. The current level of this metric is 0.20. Growth is supported by the recruitment of top marketers into the fast-growing supplements sector. Simultaneously, cbdMD, Inc. (YCBD) is implementing an eco-friendly approach, optimizing packaging and warehouse energy costs to improve raw material quality.

cbdMD Inc. - YCBD Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

cbdmd.com - analytical breakdowns and key metrics (YCBD)

- current price and projected stock value:
Stock Price cbdMD|YCBD - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization cbdMD, Inc.|YCBD - Total Company Value
- issuer book value statistics:
Book Value per Share cbdMD|YCBD - Accounting Capitalization|Market Value to Book Value Ratio cbdmd.com|YCBD - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Capital cbdMD, Inc.|YCBD - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio cbdMD|YCBD - Aggregate Debt Obligations|Debts to Book Capitalization cbdMD, Inc.|YCBD - Long-Term Debt Volume|Company Short-Term Debt cbdMD|Quick Ratio cbdmd.com
- financial results and valuation multiples details:
YCBD - Net Income|Future Profit cbdMD, Inc.|YCBD - Business Payback Period|Projected Price to Earnings cbdMD|YCBD - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple cbdMD, Inc.|YCBD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) cbdMD|YCBD - Earnings per share for the last twelve months|Quarterly EPS earnings growth cbdmd.com|YCBD - Earnings per share growth this year|Net earnings per share growth forecast for next year cbdMD, Inc.
- sales and revenue indicators:
YCBD - Company Annual Revenue|Projected Sales Volume cbdMD|YCBD - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple cbdMD, Inc.
Summary company analysis:cbdMD Corp YCBD
Product sample of cbdMD Inc.

The stable capacity utilization of cbdMD, Inc. partner plants producing CBD products allows for the correlation of the company's current market value with projected future sales via the forward P/S ratio. It is critical for investors to monitor this indicator, as it measures the efficiency of production capacity monetization, turning the trend of this forward P/S valuation into a signal of whether the asset is undervalued or overheated.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon)|KVUE - Forward Price-to-Revenue Multiple|Verona Pharma Corp - Forward P/S Multiple|MENS: Price-to-Projected Revenue Ratio|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward P/S Multiple LQDA|Galapagos Corp - Market Cap to Projected Revenue|ANI Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales MNKD|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Therapeutics) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharma (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|Market Cap to Expected Sales Ratio Tonix Pharma|China SXT Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Cap to Future Revenue Ratio|BioHarvest Sciences - Forward P/S Multiple|invizyne.com (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX (Entera Bio) - Price-to-Projected Revenue Ratio|HYFT (MindWalk) - Forward P/S Multiple|Market Cap to Projected Revenue ABVC (ABVC BioPharma, Inc)|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|QNTM: Future Price to Revenue|Forward P/S Multiple FGEN (FibroGen)|Forward Price to Sales TELO|Rani Therapeutics Inc - Forward P/S Multiple|SNYR - Forward P/S Multiple|rallybio.com (RLYB) - Price-to-Projected Revenue Ratio|Lexaria Bioscience Corp. - Forward Price to Sales|Price-to-Projected Revenue Ratio Pulmatrix|Forward Price-to-Revenue Multiple Pheton (PTHL)|Forward P/S Multiple APM|Forward P/S Multiple Lyra Therapeutics Inc (LYRA)|Impact BioMedical Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales TNFA|PRFX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Altamira Therapeutics|LIPO (Lipella) - Forward Price-to-Revenue Multiple|OPTN: Price to Expected Revenue Ratio|PIRS (Pieris Pharmaceuticals) - Forward P/S Multiple|PROC: Forward Price to Sales|Forward P/S Multiple PTPI|QLI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|Forward Price to Sales TFFP